Literature DB >> 8444672

A survey of beta-lactamases from 618 isolates of Klebsiella spp.

R Reig1, C Roy, M Hermida, D Teruel, A Coira.   

Abstract

beta-Lactamases from 618 isolates of Klebsiella spp. (487 Klebsiella pneumoniae and 131 Klebsiella oxytoca) were identified by analytical isoelectric focusing. The strains were consecutive isolates from 618 different patients in five hospital centres between 1980 and 1984. Most of the chromosomal beta-lactamases from the K. pneumoniae isolates had a pI of 7.1, and most of the K. oxytoca isolates had chromosomal beta-lactamases of pIs 7.8, 5.3 and 5.5. Plasmid-mediated beta-lactamases were produced by 91.8% of K. pneumoniae isolates and 9.9% of K. oxytoca isolates. The beta-lactamase types identified most frequently were SHV-1 in the former species, and TEM-1 in the latter species. Of the K. pneumoniae isolates, 101 produced both of these plasmid-mediated beta-lactamases, while one strain produced an extended-spectrum SHV-like beta-lactamase. Of the 131 K. oxytoca isolates, 20 were hyper-producers of chromosomal beta-lactamase. The susceptibility of this genus to beta-lactam antibiotics is controlled almost exclusively by beta-lactamases, the production of which may differ from one strain to another; thus the empirical therapeutic use of beta-lactam antibiotics is not recommended for this genus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8444672     DOI: 10.1093/jac/31.1.29

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  First description of a TEM-30 (IRT-2)-producing Klebsiella oxytoca isolate.

Authors:  Sophie A Granier; Jean-Claude Nguyen Van; Marie-Dominique Kitzis; Fred W Goldstein; Véronique Leflon-Guibout; Marie-Hélène Nicolas-Chanoine
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

2.  Identification of clinical isolates of indole-positive Klebsiella spp., including Klebsiella planticola, and a genetic and molecular analysis of their beta-lactamases.

Authors:  Y Liu; B J Mee; L Mulgrave
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

3.  Genetic characterization of resistance to extended-spectrum beta-lactams in Klebsiella oxytoca isolates recovered from patients with septicemia at hospitals in the Stockholm area.

Authors:  S W Wu; K Dornbusch; G Kronvall
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived beta-lactamase in a clinical isolate of Klebsiella oxytoca.

Authors:  H Bermudes; F Jude; E B Chaibi; C Arpin; C Bebear; R Labia; C Quentin
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

5.  SHV-1 beta-lactamase is mainly a chromosomally encoded species-specific enzyme in Klebsiella pneumoniae.

Authors:  J Chaves; M G Ladona; C Segura; A Coira; R Reig; C Ampurdanés
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 6.  Genetics of extended-spectrum beta-lactamases.

Authors:  G A Jacoby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

7.  Relationship between adhesion to intestinal Caco-2 cells and multidrug resistance in Klebsiella pneumoniae clinical isolates.

Authors:  P Di Martino; D Sirot; B Joly; C Rich; A Darfeuille-Michaud
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

Review 8.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  Beta-lactam resistance among Escherichia coli and Klebsiella species blood culture isolates in Finnish hospitals. Finnish Study Group for Antimicrobial Resistance.

Authors:  T Arstila; H Auvinen; P Huovinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-06       Impact factor: 3.267

Review 10.  Controversies about extended-spectrum and AmpC beta-lactamases.

Authors:  K S Thomson
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.